Abstract Details

Title Safety, Tolerability, and Pharmacodynamics of Intravenous and Subcutaneous Doses of the Anti-CD52 Antibody GLD52 in Patients With Progressive MS: A Randomized, Controlled, Single Ascending Dose Trial

Topic Multiple Sclerosis

Presentation(s) P5 - (-)

Poster/Presentation
Number 375

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
David H. Margolin, MD, PhD (Genzyme Corporation) PRESENTER	Dr. Margolin has received personal compensation for serving as an employee of Cerevance, Inc. Dr. Margolin has received personal compensation in the range of $0-$499 for serving as a Consultant for Datacubed Health. Dr. Margolin has received stock or an ownership interest from Cerevance, Inc. Dr. Margolin has received stock or an ownership interest from Datacubed Health. Dr. Margolin has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
Madalina Chirieac, MD	No disclosure on file
	No disclosure on file
Xiaodong Luo	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file